ZS Pharma is a biopharmaceutical company committed to the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. Our initial focus is on the development of ZS-9, our product candidate in Phase 3 development for the treatment of hyperkalemia, a potentially life-threatening condition characterized by abnormally high levels of potassium in the blood.
We are advancing ZS-9 through clinical development with the goal of obtaining approval for the treatment of acute and chronic hyperkalemia, regardless of the underlying disease state. Learn more about the results from our pivotal Phase 3 clinical trial in patients with hyperkalemia here.
Keep up to date with the latest ZS Pharma News and Updates
ZS Pharma Announces Positive Top-Line Results from HARMONIZE (ZS004), a Second Phase 3 Clinical Trial of ZS-9 in Patients with HyperkalemiaDownload PDF
ZS Pharma to Present at the 21st Annual BioCentury NewsMakers ConferenceDownload PDF
ZS Pharma Presents New Data from ZS003 a Two Week Phase 3 Trial Demonstrating that ZS-9 Prevented Recurrence of Hyperkalemia in Heart Failure Patients on RAASiDownload PDF